Holen Sie sich die Stockscreener-App
5.29
0.38%
0.02
Handel nachbörslich:
5.28
-0.010
-0.19%
Schlusskurs vom Vortag:
$5.27
Offen:
$5.27
24-Stunden-Volumen:
183.33K
Relative Volume:
0.32
Marktkapitalisierung:
$238.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.74M
KGV:
-6.4512
EPS:
-0.82
Netto-Cashflow:
$-24.89M
1W Leistung:
+1.54%
1M Leistung:
+2.52%
6M Leistung:
-52.04%
1J Leistung:
-61.50%
1-Tages-Spanne:
$5.255
$5.29
1-Wochen-Bereich:
$5.195
$5.30
52-Wochen-Spanne:
$3.18
$16.02
Third Harmonic Bio Inc Stock (THRD) Company Profile
Firmenname
Third Harmonic Bio Inc
Sektor
Branche
Telefon
(209) 727-2457
Adresse
1700 MONTGOMERY STREET, SAN FRANCISCO
Vergleichen Sie THRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
5.29 | 235.12M | 0 | -32.74M | -24.89M | -0.82 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-02-11 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-07 | Eingeleitet | Raymond James | Outperform |
| 2022-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-10 | Eingeleitet | Cowen | Outperform |
| 2022-10-10 | Eingeleitet | Jefferies | Buy |
| 2022-10-10 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Third Harmonic Bio Inc Aktie (THRD) Neueste Nachrichten
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
Third Harmonic Bio Reports Q1 2025 Financial Results - TipRanks
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Cancer drugmaker iTeos to shut down - BioPharma Dive
It’s been three months without a biotech IPO - Endpoints News
THIRD HARMONIC BIO Earnings Results: $THRD Reports Quarterly Earnings - Nasdaq
Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Third Harmonic Bio Announces Plan of Liquidation and Dissolution - ADVFN
Here’s Why Third Harmonic Bio (THRD) Fell in Q1 - Insider Monkey
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN
Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia
Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com India
Dupixent bounces back in treating hives with FDA approval - BioWorld MedTech
New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE
Biotech Alert: Searches spiking for these stocks today - TipRanks
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus
Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN
Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN
$26bn Brighton Jones hires new CFO - Citywire
Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED) - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Third Harmonic outlines plans for dissolution - BioPharma Dive
Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation - TipRanks
Third Harmonic Bio stock holds as liquidation plan unveiled By Investing.com - Investing.com Canada
Third Harmonic Bio Stock Is Up 40% Monday: What's Happening?Third Harmonic Bio (NASDAQ:THRD) - Benzinga
Third Harmonic Announces Liquidation And Cash Return, Stock Jumps - Nasdaq
Third Harmonic to shutter; Future Pak once again targets Theratechnologies - Endpoints News
THRD’s Ambitious Moves: From Trials to Strategies? - timothysykes.com
Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Third Harmonic Bio announces plan of liquidation and dissolution - TipRanks
Third Harmonic Seeks to Liquidate, Dissolve Company - marketscreener.com
Third Harmonic Bio Announces Plan Of Liquidation And Dissolution - marketscreener.com
Finanzdaten der Third Harmonic Bio Inc-Aktie (THRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Third Harmonic Bio Inc-Aktie (THRD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
0.86%
1.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):